International Journal for Doctor of Medicine and  Medical Students (IJDMMS)

Abstract

Hepatitis B is a major global public health problem caused by the Hepatitis B virus (HBV), a partially double-stranded DNA virus belonging to the Hepadnaviridae family. The disease affects the liver and may present as acute or chronic hepatitis, potentially progressing to cirrhosis, hepatic failure, and hepatocellular carcinoma. Despite the availability of an effective vaccine, HBV infection remains highly prevalent, particularly in low- and middle-income countries. This study aimed to review the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and preventive strategies of Hepatitis B with particular emphasis on vaccination as the most effective preventive measure. A narrative review methodology was adopted using data obtained from PubMed-indexed journals, WHO guidelines, CDC recommendations, and standard medical textbooks. Relevant articles published within the last two decades were analyzed. The findings demonstrate that universal vaccination significantly reduces HBV transmission, chronic carrier states, and HBV-related complications. Neonatal immunization, timely birth-dose vaccination, and vaccination of high-risk populations were identified as critical interventions. Current antiviral therapies suppress viral replication but rarely eradicate infection completely, emphasizing the importance of prevention through immunization. The review concludes that strengthening vaccination programs, improving awareness, and ensuring early diagnosis are essential for reducing the global burden of Hepatitis B. Vaccination remains the cornerstone strategy in the control and eventual elimination of HBV infection.

Keywords

Hepatitis B; Hepatitis B vaccine; Hepatitis B virus; Chronic hepatitis; Immunization; Viral hepatitis

Introduction

Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus (HBV), a hepatotropic DNA virus belonging to the Hepadnaviridae family (1). HBV infection is a major global health challenge and remains one of the most common causes of chronic liver disease worldwide (2). The infection can manifest as acute hepatitis, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) (3).

According to the World Health Organization (WHO), approximately 254 million people were living with chronic HBV infection globally in 2022, with nearly 1.2 million new infections occurring each year. HBV is responsible for approximately 1.1 million deaths annually, primarily due to complications such as cirrhosis and hepatocellular carcinoma. The disease burden is highest in the Western Pacific and African regions, although South Asia also contributes substantially to the global prevalence. World Health Organization. Hepatitis B [Internet]. Geneva: World Health Organization; 2025 Jul 23 [cited 2026 May 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

HBV transmission occurs through exposure to infected blood and body fluids. Major routes include perinatal transmission, sexual contact, unsafe injections, transfusion of contaminated blood, and intravenous drug use (4). The risk of developing chronic infection is inversely related to age at infection. Neonates infected perinatally have a 90% risk of chronicity, whereas immunocompetent adults have a significantly lower risk (5).

Vaccination against Hepatitis B represents one of the most successful preventive measures in modern medicine. Since the introduction of universal immunization programs, many countries have reported substantial reductions in HBV prevalence and related complications (6) The WHO recommends universal infant vaccination, including a timely birth dose within 24 hours of delivery(7)

Despite the effectiveness of vaccination, gaps remain in vaccine coverage, public awareness, and access to healthcare services in several developing countries (8).

The objective of this study is to review the clinical and public health aspects of Hepatitis B with particular emphasis on vaccination strategies and their importance in disease prevention.

Methodology

Study Design

This study was conducted as a narrative review of literature focusing on Hepatitis B infection and vaccination strategies.

Study Population

The review included published studies involving neonates, children, adults, healthcare workers, pregnant women, and high-risk populations affected by or vaccinated against HBV.

Inclusion Criteria

• Peer-reviewed articles related to Hepatitis B

• WHO, CDC, and NICE guidelines

• Articles discussing HBV vaccination

• English-language studies

• Studies published between 2000 and 2025

Exclusion Criteria

• Non-English publications

• Duplicate studies

• Articles without scientific validity

• Studies unrelated to vaccination or HBV prevention

Sample Size

Approximately 65 peer-reviewed articles, textbooks, and international guideline documents were screened, of which 24 highly relevant references were included.

Data Collection Methods

Data were collected from PubMed, WHO publications, CDC guidelines, and standard medical textbooks including Harrison’s Principles of Internal Medicine and Davidson’s Principles and Practice of Medicine. Keywords used included “Hepatitis B,” “HBV vaccination,” “chronic hepatitis,” and “viral hepatitis prevention.”

Statistical Analysis

Data from reviewed literature were analyzed descriptively. Epidemiological data were summarized using percentages, prevalence rates, and incidence trends. Statistical tools reported in the original studies, including SPSS-based analyses, were reviewed descriptively.

Ethical Considerations

As this study was based on previously published literature and did not involve human participants directly, formal ethical approval was not required. All sources were appropriately cited to maintain academic integrity.

Results

Epidemiological Findings

The reviewed studies showed that HBV remains highly prevalent globally, especially in developing countries.

Discussion

Hepatitis B continues to be a major cause of chronic liver disease worldwide despite the availability of effective vaccines (2). The findings of this review highlight the substantial burden of HBV infection and the critical importance of vaccination in disease prevention.

HBV primarily infects hepatocytes and induces liver injury through immune-mediated mechanisms rather than direct cytopathic effects (9). Chronic inflammation leads to fibrosis, cirrhosis, and hepatocellular carcinoma (10). Persistent viral replication and integration of viral DNA into host hepatocytes contribute significantly to carcinogenesis (11).

The reviewed literature confirms that vaccination remains the most effective preventive measure against HBV infection (12). Recombinant Hepatitis B vaccines stimulate the production of protective anti-HBs antibodies and provide long-term immunity in more than 90% of vaccinated individuals (13). Universal infant vaccination has dramatically reduced HBV prevalence in many countries, including Taiwan and China (7).

Perinatal transmission is a major route of HBV spread in endemic areas [16]. Timely administration of the birth dose vaccine within 24 hours of delivery significantly reduces mother-to-child transmission (7). In neonates born to HBsAg-positive mothers, combined administration of Hepatitis B vaccine and Hepatitis B immunoglobulin (HBIG) provides optimal protection (14)

Healthcare workers are considered a high-risk group because of occupational exposure to blood and body fluids (15). Vaccination among healthcare personnel significantly reduces nosocomial transmission and occupational HBV infection (16).

Several studies have reported declining rates of HBV-related hepatocellular carcinoma following universal vaccination programs (17). This demonstrates that vaccination not only prevents acute infection but also reduces long-term complications and mortality.

Although antiviral agents such as tenofovir and entecavir effectively suppress viral replication, they rarely eliminate covalently closed circular DNA (cccDNA), which serves as a reservoir for persistent infection (18). Therefore, preventive vaccination remains superior to treatment strategies alone.

Public health challenges include inadequate vaccine coverage, poor healthcare infrastructure, vaccine hesitancy, and lack of awareness in low-resource settings (19). Strengthening immunization campaigns and integrating HBV screening into antenatal care can significantly reduce disease transmission(20).

Suggestions / Recommendations

• Universal Hepatitis B vaccination should be implemented and strengthened in all countries.

• The birth dose vaccine should be administered within 24 hours of birth.

• Pregnant women should undergo routine screening for HBsAg during antenatal care.

• High-risk groups such as healthcare workers, dialysis patients, and intravenous drug users should receive complete vaccination.

• Public awareness campaigns should be conducted to improve vaccine acceptance.

• Safe blood transfusion practices and sterile injection techniques must be ensured.

• Booster vaccination policies should be evaluated in immunocompromised individuals.

• Early diagnosis and regular monitoring of chronic HBV patients should be encouraged.

• Governments should improve vaccine accessibility in rural and underserved populations.

• Future research should focus on curative therapies targeting HBV cccDNA.

Conclusion

Hepatitis B remains a serious global health problem associated with significant morbidity and mortality. Chronic infection may lead to cirrhosis, hepatic failure, and hepatocellular carcinoma. Vaccination is the most effective strategy for preventing HBV infection and reducing disease burden worldwide. Universal immunization, particularly timely neonatal vaccination, has substantially decreased HBV prevalence and transmission rates. Although antiviral therapies help control disease progression, prevention through vaccination remains the cornerstone of HBV control. Improved public awareness, early diagnosis, and strengthened vaccination programs are essential for the eventual elimination of Hepatitis B.

References/Bibliography

1.     Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):524–37. doi:10.1038/s41575-023-00760-9

2.     Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology & Hepatology. 2022 Sep;7(9):796–829. doi:10.1016/S2468-1253(22)00124-8

3.     Usuda D, Kaneoka Y, Ono R, Kato M, Sugawara Y, Shimizu R, et al. Current perspectives of viral hepatitis. World J Gastroenterol. 2024 May 14;30(18):2402–17. doi:10.3748/wjg.v30.i18.2402 PubMed PMID: 38764770; PubMed Central PMCID: PMC11099385.

4.     Candotti D, Boizeau L, Laperche S. Occult hepatitis B infection and transfusion-transmission risk. Transfusion Clinique et Biologique. 2017 Sep;24(3):189–95. doi:10.1016/j.tracli.2017.06.014

5.     Cryer AM, Imperial JC. Hepatitis B in Pregnant Women and their Infants. Clinics in Liver Disease. 2019 Aug;23(3):451–62. doi:10.1016/j.cld.2019.04.007

6.     Mohanty P, Jena P, Patnaik L. Vaccination against Hepatitis B: A Scoping Review. Asian Pac J Cancer Prev. 2020 Dec 1;21(12):3453–9. doi:10.31557/APJCP.2020.21.12.3453

7.     De Villiers MJ, Nayagam S, Hallett TB. The impact of the timely birth dose vaccine on the global elimination of hepatitis B. Nat Commun. 2021 Oct 28;12(1):6223. doi:10.1038/s41467-021-26475-6

8.     Wang Q, Leung K, Jit M, Wu JT, Lin L. Global socioeconomic inequalities in vaccination coverage, supply, and confidence. npj Vaccines. 2025 May 9;10(1):91. doi:10.1038/s41541-025-01143-8

9.     Thomas E, Baumert TF. Hepatitis B Virus–Hepatocyte Interactions and Innate Immune Responses: Experimental Models and Molecular Mechanisms. Semin Liver Dis. 2019 Jul;39(03):301–14. doi:10.1055/s-0039-1685518

10.   Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. WIREs Mechanisms of Disease. 2021 Jan;13(1):e1499. doi:10.1002/wsbm.1499

11.    Yeh SH, Li CL, Lin YY, Ho MC, Wang YC, Tseng ST, et al. Hepatitis B Virus DNA Integration Drives Carcinogenesis and Provides a New Biomarker for HBV-related HCC. Cell Mol Gastroenterol Hepatol. 2023;15(4):921–9. doi:10.1016/j.jcmgh.2023.01.001 PubMed PMID: 36690297; PubMed Central PMCID: PMC9972564.

12.   Qiu J, Zhang S, Feng Y, Su X, Cai J, Chen S, et al. Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses. Expert Review of Vaccines. 2024 Dec 31;23(1):69–81. doi:10.1080/14760584.2023.2289566

13.   Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Human Vaccines & Immunotherapeutics. 2020 Jul 2;16(7):1533–44. doi:10.1080/21645515.2020.1732166

14.   Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Hepato-Biliary Group, editor. Cochrane Database of Systematic Reviews. 2006 Apr 19;2010(1). doi:10.1002/14651858.CD004790.pub2

15.   Lin C, Aljuaid M, Tirada N. Needlestick injuries in radiology: prevention and management. Clinical Radiology. 2022 Jul;77(7):496–502. doi:10.1016/j.crad.2022.03.021

16.   Maltezou HC, Dounias G, Rapisarda V, Ledda C. Vaccination policies for healthcare personnel: Current challenges and future perspectives. Vaccine: X. 2022 Aug;11:100172. doi:10.1016/j.jvacx.2022.100172

17.   Abdelhamed W, El-Kassas M. Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do. Liver Research. 2024 Jun;8(2):83–90. doi:10.1016/j.livres.2024.05.004

18.   Pardo M, Bartolomé J, Carreño V. Current Therapy of Chronic Hepatitis B. Archives of Medical Research. 2007 Aug;38(6):661–77. doi:10.1016/j.arcmed.2006.12.013

19.   Al-Worafi YM. Access to Vaccines in Developing Countries. In: Al-Worafi YM, editor. Handbook of Medical and Health Sciences in Developing Countries [Internet]. Cham: Springer International Publishing; 2024 [cited 2026 May 29]. p. 1–32. Available from: https://link.springer.com/10.1007/978-3-030-74786-2_226-1 doi:10.1007/978-3-030-74786-2_226-1

20.   Thahir S, Muhindo E, Turigye B, Kabagambe K, Thompson P, Mulogo EM, et al. Implementation of Hepatitis B Screening Into Routine Antenatal Care to Prevent Mother-to-Child Transmission in Rural Western Uganda. Open Forum Infect Dis. 2023 Sep;10(9):ofad452. doi:10.1093/ofid/ofad452 PubMed PMID: 37705692; PubMed Central PMCID: PMC10496864.